Healio (4/19) reports, “Long-acting injectable [LAI] antipsychotics provided significant benefit in prevention of hospitalization or relapse for schizophrenia compared with oral antipsychotics,” researchers concluded after analyzing data from “137 studies, of which 32 were randomized controlled trials, 65 were cohort studies and 40 were pre-post studies.” The findings of the systematic review and comparable meta-analysis were published online April 13 in The Lancet Psychiatry.
Related Links:
— “LAIs more beneficial for certain schizophrenia outcomes than oral antipsychotics “Joe Gramigna, Healio, April 19, 2021